Index

African Commission, Working Group of Experts on Indigenous Populations/Communities 220–21

African Regional Intellectual Property Organization 208

Agreement on Trade-Related Aspects of Intellectual Property Rights  see TRIPS Agreement

Anti-Unfair Competition Law (China 1993, 2018) 310, 326–7

Art 1 312

Art 2 324, 325

Art 2(1), 311

Art 2(2), 311

Art 2(3), 311

Art 6 311

Art 7 311

Art 8 311

Art 9 311, 314

Art 10 311

Art 11 311

Art 12 312

Art 12(1), 323

Art 12(2), 323

Art 12(3), 323

Art 12(4), 317, 323

commercial slander 311

false advertisement 311

General Clause 310, 311–12

balance of interests 325–6

case law see China unfair competition litigation

Catchall Provision 313, 316

complementary application 313

flexibility of 313

Imperial Provision 312, 313, 316

protection of freedom of competition 311

regulation of unfair competition 316

sole application 313, 324

criticism of 313–14

limitations 316–17

Internet Clause 312, 316–17, 325–6

internet traffic hijacking 323

Junior Catchall Clause 317

likelihood of confusion 311

malicious incompatibility 323

restricting choice of users 323

unfair commercial practice 311

see also China; unfair competition

Australia

Aboriginal and Torres Strait Islander Library, Information and Resource Network 233

Corporations Act (2001) sec 180(2) 162–3

Library and Information Association protocols for handling Indigenous heritage 232–3

authors’ rights see copyright

Berne Convention 98

acceptability of fair use under 13

Appendix 2

compulsory licensing scheme 99, 105–7

criticism of 107

Art 6bis 1

Art 9(2) 13

copyright limitations & exceptions in 101, 102
Art 10(1) copyright limitations and exceptions in 101–2, 103 proportionality test 102–3
Art 14ter 79

Index

China
Anti-Unfair Competition Law see Anti-Unfair Competition Law (China 1993, 2018)
freedom of competition, boundaries 315–16
Interim Measures for Internet Advertising Management Art 16(1) 324
rapid development of internet industry 310
Supreme People’s Court’s Provisions on the Work of Guiding Case System (2010) 324
unfair internet competition litigation 310, 317–18
Baidu v. Qihoo 360 318–19, 323, 325, 326
Dianping.com v. Baidu 325
effects of precedent cases 324–5
general evaluation 323–4
judicial decision-making 323
Kelp Quota case 314–16, 317, 324–5
Tencent v. Qihoo 360 319–20, 323, 326
Tencent v. Star World Technology 320–22, 323–4
circular economy theory 144, 169
common law 3, 8
centrality of role of judges 9
copyright 8–9
exceptions 8
formalism of 8
judicial power in 11–12
compatibility with Berne Convention 12–14
compatibility with Information Society Directive 14–16
open-ended 13
restriction of 14
scope 15
statutory limitations 8
see also Berne Convention; copyright; UK
conveyancing
authors’ rights model implied transfers 49
Garcia v Google 49–50
US model
author’s signature requirement 49
deception/unconscionability 49–50
no implied transfers 49
work-made for hire 49
copying technology
and copyright exemptions 59–60
progress in 124
copyright 8–9, 141
and access to textbooks see rights to education
authors’ rights model
co-authorship 33–4
collaborative works 33–4, 37–8
contributors as authors 33
inalienability of moral rights 52
presumptive author status 33, 34
work as extension of creator 51–2
as beyond reach of human rights law 100
case law
Aalmuhammed v Lee 36–7
Childress v Taylor 36
Thomson v Larson 36
compulsory licensing 105–7
compensation 106
reproduction 106
restrictions 106–7
translation 106
creative commons
Indigenous Knowledge Notice 236
licences 236–7
share-alike provisions 70
creators’ rights 31
economic rationale 125
enabling owners to appropriate value of copying 127–8
exemptions 53, 101
advantages of 54
beneficial to mass-copying technologies 59–60
in Berne Convention 101–2
changing nature of 56, 57
digital private copying 65–7
doctrinal implications 56–7
for libraries 104–5
not compulsory 103
parody/pastiche 127
problems of 54–5
public interest 99, 101
public security 14–15
time-shifting 65
expanding subject-matter 9
fair dealing see fair dealing
fair use see fair use
fairness in see fairness
formalism of 9
Hargreaves Review 53
and human rights see human rights
limitations 101
in Berne Convention 101–2
for libraries 104–5
not compulsory 103
mainstream economic approach to 76–7
not creating monopoly power 127
opt-out rules 72–3
and tech-enabled uses 74
price control 128
and public interest 9–10
resale rights 48
restoration 50–51
and right to education see right to education
substantive rights see conveyancing;
moral rights; remuneration;
revocation rights
term of protection 41, 45
three-step test in TRIPS 103
US model 33, 34
certainty in 52
collaborative works 34
commissioned works 35
confusion over 35
considered property 49
contract negotiation 50
employer as copyright owner 34, 35
instance and expense test 36
intent to share authorship 37
joint works 36–7
not about authors’ rights 51
work-made-for-hire concept 34–6
US/authors’ rights regimes
differences 51–2
what constitutes authorship 33–4
corporate governance
accountability and transparency 152
board oversight 146–8
directors 147–8
business judgment defence 162–3
In re Walt Disney Co. 164
directors’ accountability
Revoln, Inc. v MacAndrews & Forbes Holdings, Inc 164–5
governance deficiencies 151–3
data privacy 151–2
IP policies 151
governance shortfalls 148–51
composition of board 149–50
fraud 148, 150
misconduct 151
oversight 148–9
new global regulatory discourse 151
in UK see UK corporate governance
see also IP, and corporate governance
digital libraries
challenge to online access to digital heritage 226
clash of knowledge systems 227
dominant perspective 226
IFLA/UNESCO digital Library Manifesto 229
increasingly impacting rights holder interests 226
Indigenous librarianship 227
and Indigenous peoples’ IP rights 218
concerns of source communities 227–8
digitization of TCEs 227
indigenous data sovereignty 226–9, 238–40
knowledge commons 235–8
privacy by design 234–5
Index

public sphere 240–41
respect and consultation 229
traditional cultural expressions
see traditional cultural expressions
lacking ‘natural’ restrictions on dissemination 226
see also libraries
Doha Declaration 2
emerging technologies 249, 252, 263–4
Enlightenment 220, 221
EU
-Canada Comprehensive and Economic Trade Agreement Art 8.10(2) 180
Charter 261
Art 11 29
CJEU 15
Brüstle case 255–6, 257
International Stem Cell Corporation case 257
Competition and Markets Authority 342
copyright law, and public interest 28–9
Court of Human Rights margin of appreciation doctrine 185
Directive 98/44/EC (biotechnology) 243–4, 251
Art 6 243
Art 6(2)(c) 255, 256
incorporation of Art 53(a) into EPC Implementing Regulations 252
interpretation 262
recital 26 261
recital 42 260
Directive 2001/29/EC (information society) 9–10, 12
Art 3(1), 29
Art 5(3)(e) 14–15
Art 5(3)(o) 14
Art 9 15
compatibility of common law judicial power with 14–16
exhaustive statutory limitations 15
recital 3 15
recital 31 14
recital 32 15
Directive 2014/95/EU (non-financial disclosure) 168
Directive 2019/790 (DSM) 41–2
Art 18 41
Art 19 41–42
Art 20 42
Art 22 45
Ch 3 41, 42
Directive (EU) 2016/943 (trade secrets) 288
Art 5(d) 291–2
Art 6 300
Art 7 300
Art 7(2) 299
Art 10(2) 307
Art 10(3)(a) 298
Art 11(2) 292
Art 13(1) 292, 299
Art 13(3) 300, 306
Art 14(1) 305
unfair competition approach 290
Europe 2020 Strategy 274
European Convention on Human Rights 15
food regulation
certification marks 206–7
collective mark 206
General Food Law 199–200
geographical indications 203–4
marketing 199–200
Novel Food Regulation 198–9
novel/functional foods 198–9
traditional foods from outside EU 199

G S Media v Sanoma 28–9
Horizon 2020 program 275
Intellectual Property Office 208
and open science see open science
Regulation (EU) 536/2014 (data protection) 260–61
Trademark Regulations (2009) 344
Treaty on the Functioning of the European Union
Art 101(1) 344
Art 102 342
see also certified global food chains; trade secrets
European Patent Convention 243, 247
Art 53 247, 249, 253
Art 53(a) 266
Implementing Regulations incorporation of Art 53(a) Biotechnology Directive 252
Reg 26(1) 251
Rule 28(1)(b) 259
Rule 28(1)(c) 255
Rule (28) 252
Rule 28(c) 254
morality and ordre public exceptions 243, 264
no statutory definition of morality or ordre public 247
only considering morality of commercial exploitation of invention 250
see also morality; ordre public; patents
European Patent Office
Boards of Appeal
Breast and ovarian cancer 250
guidance 247–248
OncoMouse 248
Plant cells 248
Relaxin 248
Technion 257
Transgenic Animal 248

CJEU judgments not binding 251–2
Enlarged Board of Appeal
Programs for computers 249
Transgenic plant 250
WARF 254
Examination Guidelines 257
see also morality; ordre public; patents
extraterritorial state obligations 96–7, 99–100, 109–13
in ICESCR 109
and IP law 100–101, 103, 123
in Maastrict Principles see Maastrict Principles
and right to education to facilitate 110, 113, 115–17, 118–22
to fulfil 110, 113
to protect 110–11, 113, 114
to provide 110, 111, 117–18
to respect 110, 113–14
when arising 111
see also right to education
fair and equitable treatment 193
as ambiguous standard 174, 186, 194
investment arbitration see investment arbitration
Art 1105 NAFTA standard 181
due process 181
expropriation of investment assets distinction 174
FET clauses interpretation 178, 179–80, 186–7
liability threshold 175, 177, 194
and MST 178, 179–80
referencing international law 177
stand-alone 177–8
ubiquity of 177
history 175–7
and IP 174–5
IP exclusion 174
prohibitions arbitrariness 181, 186
denial of justice 180–81
discrimination 181
protection of investor’s legitimate expectations 181–2
transparency 181
see also Canada; international investment law; NAFTA; Uruguay
fair use/dealing 9, 13, 137
case law
  Associated Press v Meltwater 68–9
  British Oxygen Co. Ltd 128–9
  Google Books cases 60–61, 67–8, 69
defence 60–61
  public benefit concept 60, 61–2
determinants 127–9
and economic growth 4, 124
effect on economic growth 131–2
  analysis 132–3
exceptions 53
  changing nature of 58
digital private copying 65–7
doctrinal implications 56–7
mass-copying technologies 60
no longer just safety net 53–4
  and tech companies 55, 57–8
temporary copying 58–9
  transfer of power 58, 65
transformative works 61, 64–5, 68
exclusivity 3, 53, 55, 56, 74–5
as frustrating purpose of fair use 67–8
  Google Books programme 60, 61, 62–3
non-replicable use 62–3, 72
potential for share-alike
  provisions 70–71
  and sole-source databases 71–2
  Turnitin/iParadigms 63–5
four pillars of
  amount and substantiality of portion used 129
effect of the use on the potential market 129
  nature of the copyrighted work 128–9
  objective and character of the use 128
Google narrative 53, 60
  implications of 129–31
  benefits 131
  costs 130–31
decreasing producer surplus 130
increase in direct costs 129
increased consumer surplus 130
loss of revenues 130
shift in supply and demand 129–30
intense lobbying for 57, 58
  as judicially created 56
  as legal term 125
market factor in 68–70
  and market power 59–60
negative impact on owner’s
  incentive 127
open-ended nature of 13
  optimal 127
  and opt-outs 72–4
  phases 127
rise of fair use industries 57–9
  technological 64
TRIPS model 126–7
  three-step test 126
UK model
  closed list, 126
  US model 54, 125–6
  open list 126
see also copyright
fairness 1, 95
  applicability to trademarks 1
  for authors and performers 31, 33
  consequentialist conception 93
  in copyright 3
  difficulty defining 32, 77, 91
  and distributive justice 77, 78, 90
  dynamism of 9
  factoring into copyright 90–95
  gap 32–3
  human rights principles as
    normative 215
  integrating welfare and 88
  La Peau de l’Ours fund 77–8
    as early resale rights system 78
    as mattering in practice 77
  measurability 93, 94
  preferences 94
    contradicting rationality models 89–90
    intermediaries 89
    visual artists 89
  public interest as proxy for 9
resale rights see resale rights
resale royalties see resale royalties
use in IP 1
voluntary payment of resale royalties 90
/welfare
incompatibility thesis 91–2
integration 92–3
/welfare maximization interaction 95
see also copyright; fair dealing; fair use; human rights

General Agreement on Tariffs and Trade 211–12
Art XX 211–12
ordre public in 212
US-Shrimp case 211

hierarchy of civilizations concept 221
human rights 4
collective rights absence in 222
education see right to education
extraterritorial state obligations see extraterritorial state obligations
Indigenous peoples’ see Indigenous peoples
principles as normative fairness 215, 217
right to education see right to education
self-determination see self-determination

ICESCR
Art 2(1) 109
Art 13 107–8, 109
acceptability in 108–9
accessibility in 108
availability in 108
human rights in 109
right to education 109
see also right to education
India, Essential Commodities Act (1955) 345
Indigenous data sovereignty 238–40, 241–2

Fairness, morality and ordre public in intellectual property

and digital libraries 239
Indigenous Navigator 238
kaitiaki 240
multifaceted nature of 238–9
operationalizing self-determination 234
knowledge commons 235–8
privacy by design 234–5
public sphere 240–41
problems of 238
rangatiratanga 240
reestablishing Indigenous authority 239–40
taonga 240
and UNDRIP 239
Waitangi Tribunal Report into Wai 262 claim 239–40
see also digital libraries; traditional cultural expressions; traditional knowledge

Indigenous peoples
as both term and movement 220–21
cultural assimilation 221
cultural destruction 221
heritage 215
#NoDAPL protests 215
and copyright 216–17
and digital libraries 218
exclusion and dispossession 215–16
intangible see below
and scientia nullius doctrine 216
systematic exclusion from IP protection 216
traditional cultural expressions see traditional cultural expressions
traditional knowledge see traditional knowledge
human rights 217
eyoung assimilationist character 222–3
enjoyment of moral and material benefits of IP 217
free prior and informed consent 217
participation 217, 222–5
Index

self-determination 217, 218, 219, 221
Indigenous/librarianship 227
Indigenous/scientific knowledge differences 225
intangible heritage and copyright 222
dominant legal framework 222, 223
IP rights
difficulties participating in norm-setting 222
difficulties with copyright 224
fight for collective rights 222
Indigenous data sovereignty see Indigenous data sovereignty
see also digital libraries
international investment law 173–5
bilateral investment treaties 176–7
international investment agreements 173
investment arbitration see investment arbitration
investment protection 173
FET standard 173
host state obligations 173
illegal expropriation 173
most-favoured-nation-treatment 173
national treatment 173
investor-state dispute settlement system 173
minimum standard of treatment 175
see also fair and equitable treatment
International Labour Organization, Convention No. 107 on Indigenous and Tribal Populations (1957) 222–3
investment arbitration
Eli Lilly v Canada 183–4, 193
arbitrariness 187
discrimination 192–3
legitimate expectations 188–90
liability threshold 194
Philip Morris v Uruguay 182–3, 193
arbitrariness 185–7
denial of justice 190–92
legitimate expectations 188
see also Canada; Uruguay
IP
5IR technology 143–4
corporate 4, 142
new era of accountability 144
and corporate governance 144–6, 169–70
best practice 61–2
board accountability 152–3
Chief IP Officer 167–8
director IP knowledge 170–72
external IP and technology advisors 166–7
Facebook Inc case 151–2
minimum acceptable IP knowledge 161–3, 164–5
technology and IP advisory boards 165–6
Theranos Inc case 148–51
crisis of legitimacy 224
international rules 2–3
as investment asset 174
and ISDS 4
law /corporate law cross-referencing 143
FET standard see fair and equitable treatment
protection
copyright see copyright
creators’ exclusive rights 124
justification for 124–5
rights see IP rights
Russia 6, 353–354
see also corporate governance
IP rights
copyright see copyright
designs 141
digital libraries see digital libraries
Indigenous peoples’ see Indigenous peoples
intangible and unseen 141
as intangible version of wealth 141
need for new approach to 144
not absolute 182
overcoming free rider problem 142–3

Daniel J. Gervais - 9781839104374
Downloaded from Elgar Online at 12/09/2021 07:06:53AM
via free access
patents 5, 141
public awareness of 141–2
societal benefits 142
source communities 216
as striking balance 143
trade secrets 141
trademarks see trademarks
ubiquity of 170

libraries
access to culture via 220
American Library Association
Bill of Rights 228
Core Values 228
Draft Principles Librarianship and
Traditional Cultural
Expressions (2009) 228–9
support for Indigenous
self-determination, 228
concept of 219
digital see digital libraries
dominant perspectives 225
functions 220
as heritage institutions 220
and Indigenous peoples’ heritage
220–21
protocols for handling 232–3
as reflecting society 226
source communities 219–20
see also traditional cultural
expressions
Maastricht Principles (2011)
extraterritorial state obligations in
96, 109–10, 111
Principle 14 113
Principle 15 111–12
Principle 17 112
Principle 29 112–13
Marrakech Treaty 3
medicines see pharmaceuticals
moral rights 1, 42–4
attribution 43
authors’ rights model
EU 42–3
France 43
integrity 43

Turner v Huston 43
US model 31, 35
extremely limited 43–4
fully waivable 44
morality 1–2, 266–7
in bioscience see biomedical
innovation
compliance 249
EU patent law 250–52
European patent law, European
Patent Convention 247, 251
exception as technologically neutral
253
exceptions rarely applied 253
innovation and legal interpretation
263–4
international patent law 244, 246–7
Paris Agreement 246
TRIPS Art 27 246–7
limitations 249–50
patent law exclusions 264–5
as policy tool 262
Biotechnology Directive
interpretation 262
germ-line intervention 263
morality-based clauses 262–3
no immunity to accepted
bioethics principles 263
patentability 263
provisions as indirect bioethics
policy tool 252
see also biomedical innovation;
ordre public; patents

North American Free Trade
Agreement
Art 1105 177, 178, 181, 183, 190
Art 1110 183
Notes of Interpretation of Certain
Chapter 11 Provisions’ (2001)
179, 190

open science, 5, 268, 286–7
Argentinian policy 281
characteristic element of 268–9
collectivism principle 271
Colombian policy 283–4
Index

access to research 284

guidelines 283
EU policy 272–5
A Digital Agenda for Europe 274
access to scientific information 273
European Open Science Cloud 275
fair competition 274
framework programs for research 272
incentives for small/independent researchers 274–5
management of IP in knowledge transfer 273
non-restrictive licensing system 274
Open Research Publishing Platform 275
publicly-funded research 274
transparency 274
Union for Innovation 274
exclusivity 271
Finnish policy 278–9
access to research 278
Open Science and Research Roadmap (2014–2017) 278
German policy 276–7
access to research 277
Digital Information initiative 276
Open Access in Deutschland strategy 277
strong protection system 276
updated copyright law 277
initiative findings 286
and IP 268–9, 271
as complementary systems 271
exclusivity 271
Mexican policy 281–2
implementation 281–2
Open Science Committee 282
no unanimous definition of 268
OECD Guidelines 284–5
Principles and Guidelines for Access to Research Data from Public Funding 284

Peruvian policy 282, 283
and IP 283
National Digital Repository for Open Access Science, Technology and Innovation 282
publicly-funded research 282–3
taxonomy of 270
transmissibility 271
US policy 279–80
corporal status of scientific progress 279
Education Resources Information Center 279
MEDLINE 279
opening of information 279–80
ordre public 1
in bioscience see biomedical innovation
compliance 249
EU Unfair Commercial Practices Directive 1
European patents case law 248
no statutory definition 248
not to be confused with public order 1
patent exception 244, 246
patent law exclusions 264–5
underlying Berne Convention 13
see also morality, patents
Organisation Africaine de la Propriété Intellectuelle 208
Organisation for Economic Co-operation and Development 197
Guidelines 284–5
Principles and Guidelines for Access to Research Data from Public Funding 284

parallel imports 114, 121–2, 344
Paris Convention (1883) 2, 246
Art 6quinquies 1
Art 7bis 210
Art 10bis 32
patents 5, 141
as administrative concessions 245
in biosciences see biomedical innovation
ethics-based rules 245–6
European Patent Convention 243 exceptions
morality see morality
ordre public see ordre public independent of market regulatory approval 245
justifications 244
limitations
compulsory license mechanisms
research exemptions 244
patent rights 245
patentability 246
see also European Patent Convention; European Patents Office
performance right 31, 40
pharmaceutical pricing 6, 330
applicability of foreign laws 333–4
Animal Science Products v. Habei Welcome Pharmaceutical Company 334
Canada 348
Alexion Pharmaceuticals Inc v. Attorney General of Canada
Patented Medicine Price Review Board 348
and competition law 339–42
abuse of dominance 333, 340, 351
Competition Act 2002 (India)
340, 341
EU 342–4
Hazel Tau & others v. GlaxoSmithKline & Boehringer Ingelheim 342
monopolies 339–40
need for intervention by competition authorities 339, 340–41, 342
no-objection certificates (India) 340–41
Shamsher Kataria v. Honda Seil and others 340
South Africa 342
unfair prices 340
cost of development to market 331
disclosure of 331–2
determining fair price 331
e-pharmacy 338
EU
Astra Zeneca v. Commission 343
Competition and Markets Authority 342
GlaxoSmithKline Services v. Commission 344
IMS Health v. NDC Health Care 343
Junek Europ-Vertrieb GmbH v Lohmann & Rauscher International GmbH & Co 344
licensing 343
Lundbeck v. Commission General Court 344
settlement agreements 344
external/international reference pricing 349–50
generic names and drugs 335–6
Activities Report of the Generic Drugs Program (FY 2018) 336
Drugs and Cosmetic Rules 1945/2018 (India) 335
International Non-proprietary Name system 335
misplaced concentration on 336
health insurance schemes 337–8
India 337
US 337–8
health technology assessments 349
India
and compulsory licences 333
cost-plus pricing 346
Drug (Prices Control) Orders 332, 345
essential medicines 345, 346
exemptions 346
information asymmetry in 346–7

Fairness, morality and ordre public in intellectual property
market-based 345
maximum retail price 346
National Pharmaceutical Pricing Authority 332, 345
price monitoring and research units 332–3
reasonably affordable price 333
standing committee on affordable medicines and health products 347–8
Uniform Code of Pharmaceuticals Marketing Practices 347
Wholesale Price Index 332
no single formula to fix prices 351
payment on value contracts 350–52
fee for service payments 351
money back guarantees 351
as unlawful inducement 351
PhRMA Guiding Principles on Direct-to-Consumer Advertisements About Prescription Medicines 331
price monitoring 332–3
Health Action International 332
Médecins Sans Frontières 332
product hopping 343–4
rapidly increasing prices 352
UK
de-branded medicines 348
statutory regulation 348
voluntary profit cap 348
US 343
and Sherman Antitrust Act (1890) 334
State of New York v. Actavis 343
The Patient Right to Know Drug Prices Act (2018) 332
Vaccine Product Price and Procurement web platform 332
value extraction 349–50
WHO Global Price Reporting Mechanism 332
pharmaceuticals 328–30
African Network for Drugs and Diagnostics Innovation 329
alternative medicine 328
diseases of the affluent 329
diseases of the poor or neglected 329
Drugs and Magic Remedies [objectionable advertisements] Act (1954) 328
Drugs for Neglected Diseases initiative 329
Medicines for Malaria Venture 329
as merited goods 350
orphan diseases 329
pricing see pharmaceutical pricing
privately-funded research 329
research/potential profit correlation 329–30
traditional medicine 328
public interest case law
Ashdown v Telegraph Group Limited 23–5, 28
Attorney General v Guardian Newspapers (Spycatcher) 19
Beggars Banquet v Carlton 21–2, 27
Beloff v Pressdram Limited 20, 28
British Leyland Motor Company Ltd v Armstrong Patent Co Ltd 25–6, 27
broadening scope of 20
Canon Kabushiki Kaisha v Green Cartridge Co (Hong Kong) Ltd 26
disclosure of information 19–20
Glynn v Weston Feature Film Co 19
Hyde Park Residence v Yelland 22–3, 24, 28
Lion Laboratories Ltd v Evans 20–21, 27
Mars UK Ltd v Teknowledge Ltd 26
Service Corporation International v Channel Four 22, 27
court readings of 18
defence 12
disclosure of copyright works 25
and EU copyright law 28–9
as fundamental principle of law 15
historical UK court use of in public
interest 18–19
public security 19
three-step test see three-step test

remuneration 38
authors’ rights model 40
additional compensation 40–41
right to equitable remuneration 41–2
term of protection 41
bargained-for payments 38
Das Boot case 40–41
US model
digital audio transmission exception 39–40
matter of contract in 38
on-demand royalties 39, 40
statutory licensing scheme 39
voluntary licensing scheme 39

resale rights
benefiting heirs of successful artists 85
and collecting societies 85–6
EU law 79–80
resale royalties see resale royalties
resale royalties 78, 79–81
applicability 80
as discrimination-reducing tools 82–3
economic effects of 84
incentives to invest 86–7
market distortions 87–8
wealth transfer 84–6
as intrinsically fair 83–4
as poverty-mitigation tools 81–2
superstar effect 85
where not applicable 80–81
revocation rights 44
authors’ rights model
EU 44–5
France 44
Germany 44
recording artists 44–5
time limits 45
US model
degree of predictability in 47
minimizing uncertainty 46
termination right 44, 45–6, 48
time limits on termination right 46–7

right to education 96
access to textbooks 96, 97–9, 107–9
bulk copying problem 103–4
copyright inhibiting 98–9
as distant dream 100
extraterritorial state obligations 113–22
and IP law 99–100
for libraries 104–5
printed books 97–8
and TRIPS norms 100
in Art 13 ICESCR 107–8, 109
acceptability in 108–9
accessibility 108
accessible higher education 108
accessible secondary education 108
availability in 108
compulsory primary education 108
copyright limitations & exceptions
applicability 119–20
in Berne Convention 101–2, 105–7, 109
no single educational 104
not compulsory 103
personal use 101
proportionality test 102–3
public interest 101
quotations 101
reproduction 102, 105–6
teaching 101–2, 120
three-step test see three-step test
translations 104, 105, 120
draft Access to Knowledge Treaty (2005) 117
as hybrid right 107
in Maastricht Principle 14 113
in Maastricht Principle 15 111–12
in Maastricht Principle 17 112
self-determination and fairness 231
as normative fairness tool 218, 226
of Indigenous peoples 217, 218, 219, 221
operationalizing 234
knowledge commons 235–8
privacy by design 234–5
public sphere 240–41
Stockholm Act (1967), UK accession to 13
Switzerland-Uruguay BIT 183

three-step test 13–14, 102–3, 114, 116, 126
certain special cases 26–8
compliance with 13
and human rights 119, 122
as guideline 16, 18
trade secrets 5, 288–90
damages see trade secrets damages
employees as threat to 288–9
EU Trade Secrets Directive 290, 309
abusive litigation 299
balancing rights and interests 294
compensation 297
continued use against guarantee
296–7
employee mobility 291
harmonization 290, 293, 298
implementation 292
injunctions 294
judicial discretion 295–6
proportionality principle 291–2, 293
remedies 291
time limits 294–5
unfair competition approach 290
final injunctions 293, 298–300
fragility of 295
injunctions 293–5, 305

as preventive 305
legislative framework for 289–90
post-employment duties 309
preliminary injunctions 293, 295–8
springboard 297–8, 299
termination 298
protection of 289
see also EU, Directive (EU) 2016/943
trade secrets damages 300–305
calculation 302
and balance of interests 304–5
non-economic factors in 303
reasonable royalty 304
in lieu of injunction 306–9
as akin to compulsory licence
307
application 306
compensation for loss 305
and ‘innocent’ third parties 308
with limitation 306
and proportionality 307
without limitation 307–8
limitation of liability 300, 301–2
safe harbour 56, 57, 351
minimum harmonization 300, 302–3
safeguards 300–301
trademarks 141
for food products 208–9
Madrid Agreement 208
Madrid Protocol 208
non-traditional 208
product shapes 208–9
traditional cultural expressions 216, 217, 224, 225, 229
access to Indigenous data 226–7, 228–9, 241–2
clash of knowledge systems 227
concerns over 227–8
creatives commons licences
236–7
culturally appropriate sharing 225
FirstVoices 233
fluid situation of 229
Indigenous data sovereignty see
Indigenous data sovereignty
Indigenous digitization 232
Indigenous labels and licences

Indigenous management of 233
Indigenous thesaurus projects 232
IsumaTV 233
Local Contexts project 233–4
mainstream libraries 232
Murkutu 233, 234
openness default 230
policy recognition of issue 228–9
protocols for handling Indigenous heritage 232–3
regulation 230
in UNDRIP 231
and copyright 222
analytical difficulties 224
lack of protection 230
cultural assimilation 221
cultural destruction 221
and fairness 229–30
legal approaches 230–31
participation 230, 231
self-determination 231
WIPO proposed sui generis regime 230

Indigenous data sovereignty see
Indigenous data sovereignty
as more than commonalities 237–8
and power relations 224, 225
practical approaches 232–4
protections of 225
proposed minimum exceptions 230

see also digital libraries; Indigenous peoples; traditional knowledge
traditional knowledge 5, 215, 234
Indigenous data sovereignty see
Indigenous data sovereignty
kaitiaki 236
labels 234
Local Context Traditional
Knowledge labels 236
licences 234
creative commons 236–7
TK/TCE common-pool resource governance 236, 237
see also digital libraries; Indigenous peoples; traditional cultural expressions

TRIPS Agreement 2, 3
absolute protection of GIs 203
Art 1.3 211
Art 7 114, 118–19, 122
Art 8 114, 118–19, 122, 210
proposed Art 8a 116
Art 9(1) 13
Art 13 103, 116
Art 15.1 208
Art 17 209
Art 27 246
Art 27(1) 188–9
Art 27.2 1
Art 30 18
Art 39.3 1
copyright protection 98
extraterritorial state obligations and
right to education 116
minimum protection of GIs 203
non-traditional trademarks 208
not imposing uniform IP standards 190
ordre public in 210
sec 104A 50, 51

UK
business model reforms 168
Companies Act (2006) 147, 155
sec 172 154–5, 165, 167, 168
Copyright Act (1956), fair dealing in 13
Copyright and Related Rights Regulations (2003) 15
Copyright Designs and Patents Act (1988)
common law powers of 11, 12
history 10–11
and public interest 10–11
sec 171(3) 9, 11–12, 14–15
context 10
sec 30 13
statutory limitations and exceptions in 11
uncertainty of Brexit impact on 14
Copyright Designs and Patents Act (1998), fair dealing 126

corporate governance see UK corporate governance

Health Service Medical Supplies (Costs) Act (2017) 348

historical court prevention of copyright 18

Human Rights Act (1998) 24

Intellectual Property Regulation Board 166

Non-Financial Reporting Regulations 168

UK corporate governance

board effectiveness reviews 157–61, 171

FRC Guidance 156, 157–8

questions for boards 158–60

business judgment rule 160–61, 163 as shield from accountability 163–4

Corporate Governance Code (2018) 154, 165
directors’ accountability 154
directors’ duties 154–5
due diligence 163
duty of care 160
good faith 155
honesty 163

express reference to IP and technology 155–6

Financial Reporting Council Corporate Culture and Role of Board recommendations 155

initiatives 156–7


standard of care 163

Stewardship Code 154, 171

see also IP, and corporate governance

UN

2030 Agenda 225

CESCR

General Comment No. 3 109

interpretation of Art 13 ICESCR 108

Charter 109

Declaration on the rights of Indigenous Peoples (2007) see UNDRIP


Sustainable Development Goals 225 see also ICESCR; Indigenous peoples; right to education

UNDRIP 217

Art 3 239

Art 13 231

Art 31 231, 239


unfair competition 44

Anti-unfair Competition Law (China) see Anti-unfair Competition Law in EU Trade

Secrets Directive 290

EU/US comparison 32

and morality 1

protection from free-riding 209

US/EU differentiation 32

Uruguay

tobacco products

80/80 regulation 185

SPR requirement 185–6

see also investment arbitration

US

Computer and Communications Industry Association 58

Copyright Act (1976) 125–6

sec 107 13, 60

sec 110(5)(b) 16


few moral rights 31

Health Care and Education and the Health Care and Education Reconciliation Act 337–8

law favoring capital over labour 31

quasi-copyright protection for older recordings 40
Patient Protection and Affordable Care Act 337, 338
Sherman Antitrust Act (1890) 334
Sound Recording Act (1971) 40
Visual Artists Rights Act 43
US–Mexico–Canada Agreement 179
Art 14.6(1) 179
Art 14.6(2) 179–80
Art 14.6(3) 190

value gap 2

WHO
Expert Advisory Panel on the International Pharmacopoeia

and Pharmaceutical Preparations 335
INN system 335

WIPO
Development Agenda 118
Draft Articles (2018)
Art 7(1) 230
minimum exception to TCE protection 230
/human rights contrast 217
need to be informed by fairness point of view 225
Performances and Phonograms Treaty 43